Jimmy Weterings, PhDPrincipal Scientist, Oligonucleotide Chemistry at AstraZeneca
Jimmy Weterings is Principal Scientist Oligonucleotide chemistry in the Discovery Sciences – Oligonucleotide chemistry team at AstraZeneca, Sweden.
Jimmy has had a tight bond with Oligonucleotides since 2002, performing research on PNA (conjugates) in the van Boom group at Leiden University and targeted SSO conjugates at Prosensa. During his Ph.D at Leiden University he synthesised and studied CpG and other TLR ligand containing conjugates. At Cenix BioScience, he developed targeted siRNA conjugates for CNS delivery. And at Cristal Therapeutics he led various projects on the (targeted) nanomedicine delivery of oligonucleotide in oncology. In 2019 he joined AstraZeneca, fully dedicating himself to the further advancement of (targeted) oligonucleotide therapeutics.
Jimmy (co-)authored 11 articles and holds several patents for drug delivery enabling technologies, including the most recent one on TMTHSI, a promising new conjugation compound for oligonucleotide and antibody conjugates.